SCHEMBL12166188

SCHEMBL12166188

CC(C)(C)N/[N+]([O-])=N/OC1CCCN(C(=O)c2ccncc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ EPHX2 P34913 3/20 0.39
▸ EPHX1 P07099 2/20 0.39
▸ POLB P06746 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ PDE4B Q07343 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ RIN1 Q13671 1/20 0.38
▸ SFRP1 Q8N474 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CSF1R P07333 1/20 0.38
▸ PDGFRB P09619 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12166178 0.81 SMN1; SMN2 (0.45) KDM4ESMN1; SMN2KMT2APOLBGAA
SCHEMBL12188108 0.81 EPHX2 (0.47) ALDH1A1KMT2AEPHX2POLBCYP3A4
SCHEMBL12166183 0.81 KMT2A (0.40) HTTKMT2AEPHX2POLBGAA
SCHEMBL12166179 0.78 EPHX2 (0.37) SMN1; SMN2KMT2AEPHX2EPHX1POLB
SCHEMBL12166185 0.77 ALDH1A1 (0.49) ALDH1A1HTTKMT2APOLBGAA
SCHEMBL12166182 0.77 LMNA (0.35) ALDH1A1MAPK1SMN1; SMN2LMNA
SCHEMBL12166158 0.75 EPHX1 (0.44) RECQLKDM4EALDH1A1MAPK1SMN1; SMN2
SCHEMBL12166159 0.73 EPHX1 (0.33) SMN1; SMN2HTTEPHX1PDE4B
SCHEMBL12166174 0.71 SMN1; SMN2 (0.44) SMN1; SMN2KMT2APOLBLMNA
SCHEMBL12166176 0.70 GAA (0.40) KMT2AGAALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8361994-B2 Primary amine diazeniumdiolate heterocyclic derivatives MERCK SHARP & DOHME CORP (US) 2013-01-29 — — US disclosed
US-8361994-B2 Primary amine diazeniumdiolate heterocyclic derivatives MERCK SHARP & DOHME CORP (US) 2013-01-29 — — US disclosed
US-20120232039-A1 PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME LLC 2012-09-13 — — US disclosed
US-20120232039-A1 PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME LLC 2012-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232039-A1 PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES EDNRA, PAH, EDNRB RECQL 2799/4885KDM4E 1197/4885ALDH1A1 1102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback